NVCR
NovoCure Limited
$12.43
0.52
(4.37%)
| Exchange: | NASDAQ |
| Market Cap: | 1.39B |
| Shares Outstanding: | 72.138M |
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Instruments & Supplies | |||||
| CEO: | Ashley Cordova | |||||
| Full Time Employees: | 1488 | |||||
| Address: |
|
|||||
| Website: | https://www.novocure.com |
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Click to read more…
Revenue Segmentation
🔒 You are currently logged out
Income Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Balance Sheet
(* All numbers are in thousands)
🔒 You are currently logged out
Cash Flow Statement
(* All numbers are in thousands)
🔒 You are currently logged out
Analyst Estimates
(* All numbers are in thousands)
🔒 You are currently logged out
Current Key Metrics
🔒 You are currently logged out
Forward P/E Ratios
🔒 You are currently logged out
SWOT Analysis
🔒 You are currently logged out
At what price to buy it? –
Intrinsic Value Calculator
🔒 Premium Feature
Log in to access the NVCR Intrinsic Value Calculator
Get comprehensive stock analysis with premium features
🔒 You are currently logged out
MS_Stock_Embed class not found. Please check plugin configuration.
